دورية أكاديمية
Implications of ACC/AHA Versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI
| العنوان: | Implications of ACC/AHA Versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI |
|---|---|
| المؤلفون: | Vallejo-Vaz, AJ, Bray, S, Villa, G, Brandts, J, Kiru, G, Murphy, J, Banach, M, De Servi, S, Gaita, D, Gouni-Berthold, I, Hovingh, GK, Jozwiak, JJ, Jukema, JW, Kiss, RG, Kownator, S, Iversen, HK, Maher, V, Masana, L, Parkhomenko, A, Peeters, A, Clifford, P, Raslova, K, Siostrzonek, P, Romeo, S, Tousoulis, D, Vlachopoulos, C, Vrablik, M, Catapano, AL, Poulter, NR, Ray, KK |
| المصدر: | 953 ; 941 |
| بيانات النشر: | Springer |
| سنة النشر: | 2022 |
| المجموعة: | Imperial College London: Spiral |
| الوصف: | Purpose Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated. Methods DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated. Results Of the 2039 patients, 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively. Conclusion In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0920-3206 |
| العلاقة: | Cardiovascular Drugs and Therapy; http://hdl.handle.net/10044/1/97688Test |
| DOI: | 10.1007/s10557-022-07343-x |
| الإتاحة: | https://doi.org/10.1007/s10557-022-07343-xTest http://hdl.handle.net/10044/1/97688Test |
| حقوق: | © The Author(s) 2022 ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.4BD86236 |
| قاعدة البيانات: | BASE |
| تدمد: | 09203206 |
|---|---|
| DOI: | 10.1007/s10557-022-07343-x |